Astellas Pharma Inc

(PINK:ALPMF)

$16.00

Created with Raphaël 2.1.2213-100100
STRONG BUY

Latest On Astellas Pharma Inc (ALPMF):

About Astellas Pharma Inc (ALPMF):

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mi read more...rabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

See Advanced Chart

General

  • Name Astellas Pharma Inc
  • Symbol ALPMF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-General
  • Full Time Employees 15,883
  • Last Split Factor5:1
  • Last Split Date2014-03-27
  • Fiscal Year EndMarch
  • Web URLhttp://www.astellas.com
View More

Valuation

  • Trailing PE 19.61
  • Forward PE 13.76
  • Price/Sales (Trailing 12 Mt.) 2.71
  • Price/Book (Most Recent Quarter) 2.48
  • Enterprise Value Revenue 0.02
  • Enterprise Value EBITDA 0.12
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin 11%
  • Return on Assets 5%
  • Return on Equity 10%
  • Earnings Per Share $0.85
  • Revenue Per Share $0
  • Gross Profit 1.02 trillion
  • Quarterly Earnings Growth -3.7%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 18
  • Environment Score 3.72
  • Social Score 10.92
  • Governance Score 6.8
  • Controversy Level 2
View More

Highlights

  • Market Capitalization 30.88 billion
  • Analyst Target Price $50
  • Book Value Per Share $6.06
View More

Share Statistics

  • Shares Outstanding 1.86 billion
  • Shares Float 1.86 billion
  • % Held by Insiders 58%
  • % Held by Institutions 56.82%
View More

Technicals

  • Beta 0.56
  • 52 Week High $17.72
  • 52 Week Low $12.68
  • 50 Day Moving Average 16.48
  • 200 Day Moving Average 15.32
View More

Dividends

  • Forward Annual Dividend Rate $0.39
  • Forward Annual Dividend Yield 2.31%
  • Payout Ratio 59%
  • Dividend Date 2018-06-18
  • ExDividend Date 2020-09-29
  • Dividend Per Share $0.34
  • Dividend Yield 0%
View More

Astellas Pharma Inc (ALPMF) Dividend Calendar:

ALPMF's last dividend payment was made to shareholders on June 18, 2018.
Astellas Pharma Inc pays out 59% of its earnings out as a dividend.

Astellas Pharma Inc (ALPMF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Astellas Pharma Inc (ALPMF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Astellas Pharma Inc (ALPMF) Chart:

Astellas Pharma Inc (ALPMF) News:

Below you will find a list of latest news for Astellas Pharma Inc (ALPMF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Astellas Pharma Inc (ALPMF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Astellas Pharma Inc (ALPMF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.